Back

Pfizer sues Aurobindo Pharma for arthritis drug patent breach in US

Friday, Jan 15, 2021

 

By Narayana Krishna

 

HYDERABAD – Pfizer Inc and associate companies have sued Aurobindo Pharmaceuticals Ltd in a US court for patent infringement of its arthritis drug Xeljanz.

 

The patent violation petition was filed on Jan 11 at the US District Court for the District court of Delaware, according to a court document reviewed by Cogencis.

 

In November, Aurobindo Pharma had informed Pfizer about filing an Abbreviated New Drug Application with the US Food & Drug

Administration, seeking approval to make a generic of Xeljanz, Tofacitinib, in 5- and 10-mg dosages.

 

Xeljanz is used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

 

Pfizer sought the injunction order to prevent Aurobindo Pharma and its US arm from making and selling the drug in the US before its patent expiry.

 

Pfizer’s patents on the said drug set to expire in 2023 and 2025.

 

At 0958 IST, shares of Aurobindo Pharma were 2.2% lower at 937.70 rupees on National Stock Exchange.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Subham Mitra

 

Cogencis Tel +91 (11) 4220-1000

Send comments to feedback@cogencis.com

.

Other News.

Facing negative net worth, Spencer’s Retail to shut loss-making stores

Informist, Thursday, Feb 22, 2024 –Source: Spencer's Retail to shut down all loss-making stores–Source: Spencer's Retail to focus only on Delhi, Kolkata, Hyderabad–Source: Spencer's Retail to shut stores due to accumulated losses–CONTEXT: Spencer's Retail consol net worth (-)5.1 bln rupees end-Dec–Source: Spencer's Retail to right-size ops at corporate level By Avishek Rakshit KOLKATA – Aiming to bounce back to the black […]

Himachal budget ups FY25 pension outgo by 10% on revert to old scheme

Informist, Thursday, Feb 22, 2024 By Krity Ambey NEW DELHI – Himachal Pradesh, in its Budget for 2024-25 (Apr-Mar), has raised the estimate of expenditure towards pension in the next fiscal year to 102.54 bln rupees, up 10% from the revised estimate of 93.18 bln rupees for the current fiscal. This comes on the back of the state's decision to switch to […]

Grasim launches Birla Opus paints, aims to be profitable in 3 years

Informist, Thursday, Feb 22, 2024 –Grasim launches paints business under 'Birla Opus' brand –Grasim Chairman Birla: Entered paints business on infra opportunity –Grasim Chairman Birla: Launching Panipat, Ludhiana, Cheyyar plants –Grasim Chairman Birla:Chamarajanagar plant to be launched by Apr-Jun –Grasim Chairman Birla: Kharagpur plant to be launched by Jan-Mar 2025 –Grasim: Launching services in Punjab, Haryana, Tamil Nadu in Mar –Grasim:To launch […]